Keros Therapeutics Stock Cash Per Share

KROS Stock

USD 57.74 0.81 1.38%

Keros Therapeutics fundamentals help investors to digest information that contributes to Keros Therapeutics' financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros Therapeutics stock.

		Last Reported	Projected for Next Year
	Cash Per Share	11.25	7.03

Cash Per Share is likely to drop to 7.03 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Keros Therapeutics Company Cash Per Share Analysis

Keros Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Cash Per Share

Total Cash

Average Shares

More About Cash Per Share | All Equity Analysis

Current Keros Therapeutics Cash Per Share

8.37 X

Most of Keros Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Keros Cash Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Keros Therapeutics is extremely important. It helps to project a fair market value of Keros Stock properly, considering its historical fundamentals such as Cash Per Share. Since Keros Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Keros Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Keros Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	1.0	0.51	-0.98	-0.85	0.92	0.85	0.85	0.95	0.61	1.0	1.0	-0.83	1.0	0.86	0.88	0.7	0.29	-0.48
Total Stockholder Equity	1.0		1.0	0.47	-0.98	-0.83	0.91	0.86	0.86	0.95	0.57	1.0	1.0	-0.84	1.0	0.88	0.88	0.68	0.31	-0.47
Net Tangible Assets	1.0	1.0		0.43	-0.97	-0.79	0.9	0.86	0.86	0.93	0.56	1.0	1.0	-0.83	1.0	0.88	0.86	0.66	0.33	-0.4
Current Deferred Revenue	0.51	0.47	0.43		-0.55	-0.8	0.47	0.16	0.16	0.65	0.87	0.45	0.49	-0.19	0.47	0.24	0.38	0.51	-0.18	-0.73
Net Debt	-0.98	-0.98	-0.97	-0.55		0.88	-0.89	-0.82	-0.82	-0.98	-0.55	-0.98	-0.98	0.84	-0.98	-0.85	-0.87	-0.67	-0.26	0.61
Retained Earnings	-0.85	-0.83	-0.79	-0.8	0.88		-0.88	-0.7	-0.7	-0.95	-0.75	-0.83	-0.84	0.73	-0.83	-0.68	-0.85	-0.8	-0.09	0.82
Accounts Payable	0.92	0.91	0.9	0.47	-0.89	-0.88		0.92	0.92	0.91	0.61	0.92	0.91	-0.89	0.91	0.86	0.97	0.82	0.35	-0.55
Long Term Debt	0.85	0.86	0.86	0.16	-0.82	-0.7	0.92		1.0	0.79	0.34	0.88	0.85	-0.97	0.86	0.83	0.95	0.79	0.31	-0.34
Long Term Debt Total	0.85	0.86	0.86	0.16	-0.82	-0.7	0.92	1.0		0.79	0.34	0.88	0.85	-0.97	0.86	0.83	0.95	0.79	0.31	-0.34
Capital Surpluse	0.95	0.95	0.93	0.65	-0.98	-0.95	0.91	0.79	0.79		0.63	0.95	0.95	-0.83	0.95	0.83	0.88	0.72	0.23	-0.69
Total Liab	0.61	0.57	0.56	0.87	-0.55	-0.75	0.61	0.34	0.34	0.63		0.56	0.59	-0.26	0.57	0.3	0.51	0.67	-0.13	-0.46
Net Invested Capital	1.0	1.0	1.0	0.45	-0.98	-0.83	0.92	0.88	0.88	0.95	0.56		1.0	-0.86	1.0	0.88	0.89	0.69	0.32	-0.46
Total Current Assets	1.0	1.0	1.0	0.49	-0.98	-0.84	0.91	0.85	0.85	0.95	0.59	1.0		-0.83	1.0	0.87	0.87	0.68	0.31	-0.47
Capital Stock	-0.83	-0.84	-0.83	-0.19	0.84	0.73	-0.89	-0.97	-0.97	-0.83	-0.26	-0.86	-0.83		-0.84	-0.84	-0.93	-0.75	-0.32	0.45
Net Working Capital	1.0	1.0	1.0	0.47	-0.98	-0.83	0.91	0.86	0.86	0.95	0.57	1.0	1.0	-0.84		0.88	0.87	0.67	0.32	-0.46
Short Term Debt	0.86	0.88	0.88	0.24	-0.85	-0.68	0.86	0.83	0.83	0.83	0.3	0.88	0.87	-0.84	0.88		0.79	0.44	0.71	-0.37
Common Stock	0.88	0.88	0.86	0.38	-0.87	-0.85	0.97	0.95	0.95	0.88	0.51	0.89	0.87	-0.93	0.87	0.79		0.87	0.22	-0.58
Property Plant Equipment	0.7	0.68	0.66	0.51	-0.67	-0.8	0.82	0.79	0.79	0.72	0.67	0.69	0.68	-0.75	0.67	0.44	0.87		-0.2	-0.52
Net Receivables	0.29	0.31	0.33	-0.18	-0.26	-0.09	0.35	0.31	0.31	0.23	-0.13	0.32	0.31	-0.32	0.32	0.71	0.22	-0.2		0.08
Deferred Long Term Liab	-0.48	-0.47	-0.4	-0.73	0.61	0.82	-0.55	-0.34	-0.34	-0.69	-0.46	-0.46	-0.47	0.45	-0.46	-0.37	-0.58	-0.52	0.08

Click cells to compare fundamentals

Keros Cash Per Share Historical Pattern

Today, most investors in Keros Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Keros Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Keros Therapeutics cash per share as a starting point in their analysis.

Keros Therapeutics Cash Per Share

Timeline

Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Competition

Predict Keros Therapeutics

Cash Per Share Over Time

Keros Common Stock Shares Outstanding

Common Stock Shares Outstanding

20.4 Million

At this time, Keros Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Keros Therapeutics has a Cash Per Share of 8.37 times. This is 92.41% higher than that of the Biotechnology sector and 93.3% higher than that of the Health Care industry. The cash per share for all United States stocks is 67.07% lower than that of the firm.

Keros Cash Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.

Keros Therapeutics is currently under evaluation in cash per share category among its peers.

Keros Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		172.6M	828.8M	1.1B	946.3M	854.1M	545.9M

Keros Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Keros Fundamentals

	Return On Equity	-0.44
	Return On Asset	-0.28
	Operating Margin	(151.18) %
	Current Valuation	1.86 B
	Shares Outstanding	40.51 M
	Shares Owned By Insiders	5.40 %
	Shares Owned By Institutions	94.60 %
	Number Of Shares Shorted	2.22 M
	Price To Book	4.45 X
	Price To Sales	3,643 X
	Revenue	151 K
	Gross Profit	(87.27 M)
	EBITDA	(152.18 M)
	Net Income	(152.99 M)
	Cash And Equivalents	215.62 M
	Cash Per Share	8.37 X
	Total Debt	14.44 M
	Debt To Equity	0 %
	Current Ratio	14.39 X
	Book Value Per Share	13.57 X
	Cash Flow From Operations	(124.51 M)
	Short Ratio	5.73 X
	Earnings Per Share	(5.22) X
	Target Price	90.69
	Number Of Employees	160
	Beta	1.24
	Market Capitalization	2.37 B
	Total Asset	370.02 M
	Retained Earnings	(381.43 M)
	Working Capital	322.92 M
	Current Asset	11.95 M
	Current Liabilities	5.72 M
	Net Asset	370.02 M

About Keros Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC